The primary objective of the study was to determine the feasibility of administering VSLI to relapsed or refractory AML patients having failed, refused or not a candidate for at least one chemotherapy salvage regimen. Feasibility was defined as at least four of the first 10 patients able to complete two cycles to allow the study to continue. Secondary objectives included the hematologic improvement rate of VSLI in this patient population, the response rate (CR, CRi, partial remission (PR), and morphologic leukemia-free state (MLFS)) and overall survival of patients treated with VSLI.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.